Analyst Reco. Akeso, Inc.

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:14 09/07/2025 pm IST			5-day change	1st Jan Change
109.80 ^HKD	0.00%		+19.41%	+80.89%

03/07	Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports	RE
03/07	Akeso's First Bispecific Adc (Trop2/Nectin4 Adc) Enters Clinical Trials, Strengthening Leadership in 'Io+Adc'2.0 Strategy	CI

Analyst Reco.

Nomura Downgrades Akeso to Neutral From Buy, Adjusts Price Target to HK$99.66 From HK$75.14	28/04	MT
Nomura Adjusts Akeso's Price Target to HK$75.14 From HK$66.40, Keeps at Buy	18/02	MT
GF Securities Starts Akeso at Buy with HK$81.59 Price Target	11/12	MT
Nomura Adjusts Akeso's Price Target to HK$66.40 From HK$46.04, Keeps at Buy	10/24/10	MT
Nomura Adjusts Akeso's Price Target to HK$46.04 From HK$52.80, Keeps at Buy	16/24/16	MT
Nomura Adjusts Akeso’s Price Target to HK$52.80 From HK$48.84, Keeps at Buy	23/24/23	MT
Nomura Adjusts Akeso's Price Target to HK$48.84 From HK$50.14, Keeps at Buy	26/23/26	MT
Nomura Adjusts Akeso's Price Target to HK$50.14 From HK$46.04, Keeps at Buy	23/23/23	MT
Nomura Adjusts Akeso's Price Target to HK$46.04 From HK$31.54, Keeps at Buy	07/22/07	MT
Nomura Adjusts Akeso's Price Target to HK$31.54 From HK$35.81, Keeps at Buy	24/22/24	MT
UBS Adjusts Akeso’s Price Target to HK$26.68 From HK$29.60, Keeps at Buy	08/22/08	MT
UBS Adjusts Akeso’s Price Target to HK$29.60 From HK$32.40, Keeps at Buy	05/22/05	MT
Nomura Adjusts Akeso's Price Target to HK$35.81 From HK$53.66, Keeps at Buy	01/22/01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

All our actual portfolios continue to outperform their benchmark.

Discover our performance

Discover our performance